GlassScriptPhysician profile
Ayman Hamad
NPI 1447218326
$9,174.56
in general payments reported to CMS, 2019-2025
24 companies · $19.91 in 2025
The $19.91 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $183 · 2022: $4,555 · 2023: $3,382 · 2024: $1,035 · 2025: $19.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,436.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,056.22 | 2022-2023 | Linq II, Corevalve Evolut R, Micra |
| E.R. Squibb & Sons, L.L.C. | $1,264.96 | 2022-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $1,020.90 | 2022-2024 | Farxiga, Andexxa |
| Pfizer INC. | $627.08 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $624.99 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $560.04 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.13 | 2022-2024 | Jardiance |
| Novo Nordisk INC | $396.07 | 2022-2024 | Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $292.74 | 2022-2024 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $285.47 | 2022-2023 | |
| Actelion Pharmaceuticals US, INC. | $247.79 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $207.79 | 2023 | Arcalyst |
| Boston Scientific Corporation | $207.46 | 2022 | |
| Amgen INC. | $198.11 | 2022-2024 | Repatha |
| Merck Sharp & Dohme LLC | $176.01 | 2022-2024 | Verquvo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $159.57 | 2022 | |
| Alnylam Pharmaceuticals INC. | $135.96 | 2022 | |
| Amarin Pharma, INC. | $83.80 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $66.10 | 2024 | Arcalyst |
| Cvrx, INC. | $49.85 | 2024-2025 | Barostim Neo System |
| Alexion Pharmaceuticals, INC. | $44.95 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $23.08 | 2023 | Inpefa |
| Scpharmaceuticals INC. | $22.48 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $13.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Hamad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.